Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer

Häntschel, M. ORCID: https://orcid.org/0000-0002-0610-1959, Niebling, J., Häring, A., Häring, M-F., Groß, T., Horger, M., Riessen, R., Haap, M., Lewis, Richard, Böckeler, M. and Hetzel, J. (2020) Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer. Thoracic cancer, 11 (7). pp. 2044-2047. ISSN 1759-7714

Preview

Text (Version of Record) Lewis-2020-Life-threatening-pneumonitis-after-first-line-treatment-with-osimertinib-for-primary-T790M-mutated-non-small-cell-lung-cancer.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (636kB) | Preview

Abstract

Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority of patients, severe and even life-threatening side effects have been reported. TKI-induced interstitial lung disease (ILD) has been reported for single cases in modest severity, predominantly in EGFR-TKI pretreated patients. Here, we report a case of successful stabilization of a life-threatening ILD in a de novo T790M mutated NSCLC during first-line treatment with osimertinib. As osimertinib will be used more often in many EGFR-positive NSCLC patients in the future, this potentially life-threatening side effect should receive special attention, especially in first-line treatment

Actions (login required)

View Item